View Expired Tender

Get immediate access to tenders like the one below by subscribing now to Tenders Direct. We will set up your personalised profile and send you tender alerts direct to your mailbox as soon as they are published. You will also benefit from having access to historical tenders.

Notice Summary

Title:
United Kingdom-Runcorn: NHS National Pharmaceuticals Transition 2019_2
Document Ref:
447386-2019
Document Type:
Contract Notice - Open Procedure
Published By:
The NHS Commissioning Board (operating under the name of NHS England)
Date Published:
24 September 2019
Deadline Date:
28 October 2019
Document Source:
Framework/DPS:
Yes
Alert Profile:
Labels:

Notice Abstract

NHS National Pharmaceuticals Transition 2019_2Offer reference number: CM/PHG/17/5548Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.Potential periods of call-offs under the framework agreement:— NWLN: 1.2.2020 to 30.9.2020 (8 months),— LSNE: 1.2.2020 to 28.2.2021 (13 months),— CESW: 1.2.2020 to 31.10.2021 (21 months).Products on the framework include (but are not limited to):— Azacitadine,— Colesevelam hcl,— Deferiprone,— Ezetimibe + simvastatin,— Fosamprenavir calcium,— Lopinavir + ritonavir,— Oxybutinin patches,— Parecoxib,— Posaconazole,— Roflumilast,— Sodium oxybate,— Vildagliptin + metformin,— Vinflunine ditartrate,— Vinorelbine (oral).

Notice Details

Contract notice

Directive 2014/24/EU - Public Sector Directive

Directive 2014/24/EU

Section I: Contracting Change entity

I.1) Name and addresses

The NHS Commissioning Board (operating under the name of NHS England)

2nd Floor, Rutland House

Runcorn

WA7 2ES

UK

E-mail: david.ford1@nhs.net

NUTS: UK

Internet address(es)

Main address: https://nhsengland.bravosolution.co.uk

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

The procurement documents are available for unrestricted and full direct access, free of charge at:

https://nhsengland.bravosolution.co.uk


Additional information can be obtained from the abovementioned address


Tenders or requests to participate must be sent electronically to:

https://nhsengland.bravosolution.co.uk


Tenders or requests to participate must be sent to the abovementioned address


I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

NHS National Pharmaceuticals Transition 2019_2

Reference number: CM/PHG/17/5548

II.1.2) Main CPV code

33600000

 

II.1.3) Type of contract

Supplies

II.1.4) Short description

NHS National Pharmaceuticals Transition 2019_2

Offer reference number: CM/PHG/17/5548

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

— NWLN: 1.2.2020 to 30.9.2020 (8 months),

— LSNE: 1.2.2020 to 28.2.2021 (13 months),

— CESW: 1.2.2020 to 31.10.2021 (21 months).

Products on the framework include (but are not limited to):

— Azacitadine,

— Colesevelam hcl,

— Deferiprone,

— Ezetimibe + simvastatin,

— Fosamprenavir calcium,

— Lopinavir + ritonavir,

— Oxybutinin patches,

— Parecoxib,

— Posaconazole,

— Roflumilast,

— Sodium oxybate,

— Vildagliptin + metformin,

— Vinflunine ditartrate,

— Vinorelbine (oral).

II.1.5) Estimated total value

Value excluding VAT: 123 340 000.00 GBP

II.1.6) Information about lots

This contract is divided into lots: Yes

Tenders may be submitted for all lots

II.2) Description

Lot No: 01

II.2.1) Title

NWLN: 1.2.2020 to 30.9.2020 (8 Months)

II.2.2) Additional CPV code(s)

33600000

33690000

II.2.3) Place of performance

NUTS code:

UKD

UKH

UKI

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) Description of the procurement

NHS National Pharmaceuticals Transition 2019_2

Offer reference number: CM/PHG/17/5548

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

— NWLN: 1.2.2020 to 30.9.2020 (8 months),

— LSNE: 1.2.2020 to 28.2.2021 (13 months),

— CESW: 1.2.2020 to 31.10.2021 (21 months).

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: 23 340 000.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020

End: 30/09/2020

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options:

This framework has the options for the NWLN region to extend for up to a maximum of 8 months.

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 02

II.2.1) Title

LSNE: 1.2.2020 to 28.2.2021 (13 Months)

II.2.2) Additional CPV code(s)

33600000

33690000

II.2.3) Place of performance

NUTS code:

UKC

UKE

UKI

UKJ

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) Description of the procurement

NHS National Pharmaceuticals Transition 2019_2

Offer reference number: CM/PHG/17/5548

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

— NWLN: 1.2.2020 to 30.9.2020 (8 months),

— LSNE: 1.2.2020 to 28.2.2021 (13 months),

— CESW: 1.2.2020 to 31.10.2021 (21 months).

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: 40 000 000.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020

End: 28/02/2021

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options:

This framework has the options for the LSNE region to extend for up to a maximum of 13 months.

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Lot No: 03

II.2.1) Title

CESW: 1.2.2020 to 31.10.2021 (21 months).

II.2.2) Additional CPV code(s)

33600000

33690000

II.2.3) Place of performance

NUTS code:

UKF

UKG

UKK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) Description of the procurement

NHS National Pharmaceuticals Transition 2019_2

Offer reference number: CM/PHG/17/5548

Period of framework agreement: the total maximum duration of the framework agreement to be no more than 42 months.

Potential periods of call-offs under the framework agreement:

— NWLN: 1.2.2020 to 30.9.2020 (8 months),

— LSNE: 1.2.2020 to 28.2.2021 (13 months),

— CESW: 1.2.2020 to 31.10.2021 (21 months).

II.2.5) Award criteria

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) Estimated value

Value excluding VAT: 60 000 000.00 GBP

II.2.7) Duration of the contract, framework agreement or dynamic purchasing system

Start: 01/02/2020

End: 31/10/2021

This contract is subject to renewal: No

II.2.9) Information about the limits on the number of candidates to be invited

II.2.10) Information about variants

Variants will be accepted: No

II.2.11) Information about options

Options: Yes

Description of options:

This framework has the options for the CESW region to extend for up to a maximum of 21 months.

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Open procedure

IV.1.3) Information about a framework agreement or a dynamic purchasing system

The procurement involves the establishment of a framework agreement with several operators.

IV.1.8) Information about Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

IV.2) Administrative information

IV.2.2) Time limit for receipt of tenders or requests to participate

Date: 28/10/2019

Local time: 13:00

IV.2.4) Languages in which tenders or requests to participate may be submitted

EN

IV.2.6) Minimum time frame during which the tenderer must maintain the tender

Duration in months: 3 (from the date stated for receipt of tender)

IV.2.7) Conditions for opening of tenders

Date: 28/10/2019

Local time: 13:00

Place:

Runcorn.

Information about authorised persons and opening procedure:

Commercial medicines unit employee.

Section VI: Complementary information

VI.1) Information about recurrence

This is a recurrent procurement: No

VI.2) Information about electronic workflows

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

VI.3) Additional information

Responding to this notice:

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information.

This procurement exercise will be conducted on the eTendering portal at https://nhsengland.bravosolution.co.uk

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at https://nhsengland.bravosolution.co.uk/web/login.html and click the link to register:

— accept the terms and conditions and click continue,

— enter your correct business and user details,

— note the username you chose and click ‘Save’ when complete,

— you will shortly receive an email with your unique password (please keep this secure);

1.2) Once registered, candidates must express interest as follows:

(a) login to the eTendering portal;

(b) select ‘Response to ITT’;

(c) select ‘ITTs Open To All Suppliers’;

(d) access listing related to this procurement, NHS National Pharmaceuticals Transition 2019_2 and view details;

(e) click on ‘Express interest’ button at the top of the page;

(f) once you have expressed interest, the ITT will move to ‘My ITTs’, where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the ‘Publish’ button;

1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 8003684850 or help@bravosolution.co.uk

2) General supplier information:

To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Government's Supplier Registration Service (which has replaced sid4gov), as follows:

2.1) If not already registered (the previous sid4gov password, login and details will still be on the system), candidates must go to the following web page https://supplierregistration.cabinetoffice.gov.uk and select ‘Register’ at the top of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun and Bradstreet (D&B) D-U-N-S® Number to enable registration on the system:

2.2) Once registration is complete you are able to create and update your company profile. Candidates should ensure all the mandatory fields of their profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B;

2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at:

support@nqc.com or telephone +44 (0) 8452992994.

Other contracting authorities:

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

VI.4) Procedures for review

VI.4.1) Review body

The Royal Courts of Justice

London or any other district registry of the High Court

UK

VI.5) Date of dispatch of this notice

20/09/2019

Current Notes